Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free

British Journal of Cancer

Volumn 83, Issue 11, 2000, Pages 1432-1436

  Doherty, A P ^a   Bower, M ^b   Smith, G L ^a   Miano, R ^a   Mannion, E M ^a   Mitchell, H ^a   Christmas, T J ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Prostate cancer; PSA nadir; Radical retropubic prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HORMONAL THERAPY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0033670392     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1474     Document Type: Article

References (33)

1. The Immulite assay tube: A new approach to heterogeneous ligand assay
2. Nerve-sparing radical prostatectomy: Evaluation of results after 250 patients
3. 5-Year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
4. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
5. Relationship between prostate-specific antigen, prostate volume and age in the benign prostate
6. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins
7. Consensus statement: Guidelines for PSA following radiation therapy
8. The combination of pre-operative prostate-specific antigen and post-operative pathological findings to predict prostate-specific antigen outcome in clinically localised prostate cancer
9. Hazard rates for progression determined by PSA, after radical prostatectomy for T1-T2 prostate cancer
10. Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy
11. Radical prostatectomy with preservation of sexual function: Pathological findings in the first 100 cases
12. A review of radical prostatectomy from three centres in the UK: Clinical presentation and outcome
13. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: Potential applications in prostate and breast cancer
14. Prognostic implications of a positive apical margin in radical prostatectomy specimens
15. Is prostate-specific antigen of clinical importance in evaluating outcome after radical prostatectomy?
16. Histologic grading and clinical staging of carcinoma of the prostate
17. Early prostate-specific antigen after radical retropublic prostatectomy: Prediction on the basis of preoperative and postoperative tumor characteristics
18. Extraprostatic localisation of prostatic acid phosphatase and prostate-specific antigen: Distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland
19. The periurethral glands do not significantly influence the serum prostate specific antigen concentration
20. Prostate-specific antigen in the staging of localised prostate cancer: Influence of tumour differentiation, tumour volume and benign hyperplasia
21. Serum PSA after anatomic radical prostatectomy
22. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localised prostate cancer. Multi-institutional update
23. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate-specific antigen doubling times and log slope prostate-specific antigen
24. PSA following anatomical radical prostatectomy: Patterns of recurrence and cancer control
25. Natural history of progression after PSA elevation following radical prostatectomy
26. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens
27. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-T2 prostate cancer
28. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique
29. Early detection of cancer relapse after prostatectomy using very sensitive prostate-specific antigen measurements
30. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies
31. Measurement of serum prostate-specific antigen levels in women and in prostatectomised men with an ultrasensitive immunoassay technique
32. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy
33. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 mG./L